TPST

Tempest Therapeutics (TPST)

About Tempest Therapeutics (TPST)

Tempest Therapeutics, Inc. is a clinical-stage oncology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a wide range of tumors. The company’s novel programs range from early research to later-stage investigation in a randomized global study in first-line cancer patients. Tempest Therapeutics was founded in 2011 and is headquartered in Brisbane, CA.

Details

Daily high
$3.06
Daily low
$2.92
Price at open
$2.92
52 Week High
$13.65
52 Week Low
$2.87
Market cap
14.3M
Dividend yield
0.00%
Volume
82,700
Avg. volume
264,226
P/E ratio
-.29

Tempest Therapeutics News

Details

Daily high
$3.06
Daily low
$2.92
Price at open
$2.92
52 Week High
$13.65
52 Week Low
$2.87
Market cap
14.3M
Dividend yield
0.00%
Volume
82,700
Avg. volume
264,226
P/E ratio
-.29